Background The incidence of adenocarcinomas of the distal esophagus, gastroesophageal junction (GEJ), and stomach diagnosed before age 50 years is increasing and early-onset disease may have a distinct phenotype. A comprehensive synthesis of clinicopathological and molecular differences between early-onset and average-...
F. Petrelli, L. Dottorini, S. Cherri et al.· ESMO gastrointestinal oncolo...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and activating KRAS mutations occur in more than 90% of tumors. Direct RAS targeting has moved from proof of concept to randomized clinical benefit: in previously treated metastatic PDAC, daraxonrasib improved median overall survival, p...
F. Petrelli, L. Dottorini, A. Zaniboni· Cancer· 0 citations
Simple Summary When cancer returns after immune checkpoint inhibitor treatment given around curative surgery, clinicians often have little direct evidence to guide the next therapy. This review examines melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial carcinoma, and triple-negative breast cancer....
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
Within RCC, bladder cancer, and NSCLC, next-generation PD-(L)1 combinations are reshaping treatment across all disease stages, and the magnitude of benefit, the relevant biomarkers, and the toxicity trade-offs differ substantially by tumor type and by setting.
F. Petrelli, Lara Colombo Zefinetti, A. D'Alessio et al.· Current Oncology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
